Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Robert J. Motzer, M.D., Thomas E. Hutson, D.O., Pharm.D., Piotr Tomczak, M.D., M. Dror Michaelson, M.D., Ph.D., Ronald M. Bukowski, M.D., Olivier Rixe, M.D., Ph.D., Stéphane Oudard, M.D., Ph.D., Sylvie Negrier, M.D., Ph.D., Cezary Szczylik, M.D., Ph.D., Sindy T. Kim, B.S., Isan Chen, M.D., Paul W. Bycott, Dr.P.H., Charles M. Baum, M.D., Ph.D., and Robert A. Figlin, M.D.
Background Since sunitinib malate has shown activity in twouncontrolled studies in patients with metastatic renal-cellcarcinoma, a comparison of the drug with interferon alfa ina phase 3 trial is warranted.
Methods We enrolled 750 patients with previously untreated,metastatic renal-cell carcinoma in a multicenter, randomized,phase 3 trial to receive either repeated 6-week cycles of sunitinib(at a dose of 50 mg given orally once daily for 4 weeks, followedby 2 weeks without treatment) or interferon alfa (at a doseof 9 MU given subcutaneously three times weekly). The primaryend point was progression-free survival. Secondary end pointsincluded the objective response rate, overall survival, patient-reportedoutcomes, and safety.
Results The median progression-free survival was significantlylonger in the sunitinib group (11 months) than in the interferonalfa group (5 months), corresponding to a hazard ratio of 0.42(95% confidence interval, 0.32 to 0.54; P<0.001). Sunitinibwas also associated with a higher objective response rate thanwas interferon alfa (31% vs. 6%, P<0.001). The proportionof patients with grade 3 or 4 treatment-related fatigue wassignificantly higher in the group treated with interferon alfa,whereas diarrhea was more frequent in the sunitinib group (P<0.05).Patients in the sunitinib group reported a significantly betterquality of life than did patients in the interferon alfa group(P<0.001).
Conclusions Progression-free survival was longer and responserates were higher in patients with metastatic renal-cell cancerwho received sunitinib than in those receiving interferon alfa(ClinicalTrials.gov numbers, NCT00098657
[ClinicalTrials.gov]
and NCT00083889
[ClinicalTrials.gov]
).
Source Information
From the Memorial Sloan-Kettering Cancer Center, New York (R.J.M.); Baylor Sammons Cancer Center–Texas Oncology, Dallas (T.E.H.); Klinika Onkologii Oddzial Chemioterapii, Poznan, Poland (P.T.); Massachusetts General Hospital Cancer Center, Boston (M.D.M.); Cleveland Clinic Foundation, Cleveland (R.M.B.); Hôpital Pitié–Salpêtrière (O.R.) and Hôpital Européen Georges Pompidou (S.O.) — both in Paris; Centre Léon Bérard, Lyon, France (S.N.); Military Institute of Medicine, Warsaw, Poland (C.S.); Pfizer Global Research and Development, La Jolla, CA (S.T.K., I.C., P.W.B., C.M.B.); and City of Hope Comprehensive Cancer Center, Los Angeles (R.A.F.).
Address reprint requests to Dr. Motzer at the Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021, or at motzerr{at}mskcc.org.
Birk, D. M., Barbato, J., Mureebe, L., Chaer, R. A.
(2009). Basic Science Review: Current Insights on the Biology and Clinical Aspects of VEGF Regulation. VASC ENDOVASCULAR SURG
42: 517-530
[Abstract]
Larkin, J. M.G., Kipps, E. L.S., Powell, C. J., Swanton, C.
(2009). Review: Systemic therapy for advanced renal cell carcinoma. Therapeutic Advances in Medical Oncology
1: 15-27
[Abstract]
George, S., Merriam, P., Maki, R. G., Van den Abbeele, A. D., Yap, J. T., Akhurst, T., Harmon, D. C., Bhuchar, G., O'Mara, M. M., D'Adamo, D. R., Morgan, J., Schwartz, G. K., Wagner, A. J., Butrynski, J. E., Demetri, G. D., Keohan, M. L.
(2009). Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas. JCO
27: 3154-3160
[Abstract][Full Text]
Rini, B. I.
(2009). Metastatic Renal Cell Carcinoma: Many Treatment Options, One Patient. JCO
27: 3225-3234
[Abstract][Full Text]
Castellano, D., del Muro, X. G., Perez-Gracia, J. L., Gonzalez-Larriba, J. L., Abrio, M. V., Ruiz, M. A., Pardo, A., Guzman, C., Cerezo, S. D., Grande, E.
(2009). Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population. Ann Oncol
0: mdp067v1-mdp067
[Abstract][Full Text]
Zhu, A. X., Sahani, D. V., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Catalano, O. A., Sindhwani, V., Blaszkowsky, L. S., Yoon, S. S., Lahdenranta, J., Bhargava, P., Meyerhardt, J., Clark, J. W., Kwak, E. L., Hezel, A. F., Miksad, R., Abrams, T. A., Enzinger, P. C., Fuchs, C. S., Ryan, D. P., Jain, R. K.
(2009). Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study. JCO
27: 3027-3035
[Abstract][Full Text]
Yeh, E. T.H., Bickford, C. L.
(2009). Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management.. J Am Coll Cardiol
53: 2231-2247
[Abstract][Full Text]
Park, C. M., Goo, J. M., Lee, H. J., Kim, M. A, Kim, H.-C., Kim, K. G., Lee, C. H., Im, J.-G.
(2009). FN13762 Murine Breast Cancer: Region-by-Region Correlation of First-Pass Perfusion CT Indexes with Histologic Vascular Parameters. Radiology
251: 721-730
[Abstract][Full Text]
Chi, A. S., Sorensen, A. G., Jain, R. K., Batchelor, T. T.
(2009). Angiogenesis as a Therapeutic Target in Malignant Gliomas. The Oncologist
14: 621-636
[Abstract][Full Text]
Di Lorenzo, G., Autorino, R., Bruni, G., Carteni, G., Ricevuto, E., Tudini, M., Ficorella, C., Romano, C., Aieta, M., Giordano, A., Giuliano, M., Gonnella, A., De Nunzio, C., Rizzo, M., Montesarchio, V., Ewer, M., De Placido, S.
(2009). Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol
0: mdp025v1-mdp025
[Abstract][Full Text]
Hanrahan, E. O., Ryan, A. J., Mann, H., Kennedy, S. J., Langmuir, P., Natale, R. B., Herbst, R. S., Johnson, B. E., Heymach, J. V.
(2009). Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non-Small Cell Lung Cancer. Clin. Cancer Res.
15: 3600-3609
[Abstract][Full Text]
Izzedine, H., Ederhy, S., Goldwasser, F., Soria, J. C., Milano, G., Cohen, A., Khayat, D., Spano, J. P.
(2009). Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol
20: 807-815
[Abstract][Full Text]
McDermott, U., Ames, R. Y., Iafrate, A. J., Maheswaran, S., Stubbs, H., Greninger, P., McCutcheon, K., Milano, R., Tam, A., Lee, D. Y., Lucien, L., Brannigan, B. W., Ulkus, L. E., Ma, X.-J., Erlander, M. G., Haber, D. A., Sharma, S. V., Settleman, J.
(2009). Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-{alpha} Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase Inhibitors. Cancer Res.
69: 3937-3946
[Abstract][Full Text]
SCHMIDINGER, M., BOJIC, A., VOGL, U. M, LAMM, W., ZIELINSKI, C. C.
(2009). Management of Cardiac Adverse Events Occurring with Sunitinib Treatment. Anticancer Res
29: 1627-1629
[Abstract][Full Text]
Burkitt, K., Chun, S. Y., Dang, D. T., Dang, L. H.
(2009). Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment. Molecular Cancer Therapeutics
8: 1148-1156
[Abstract][Full Text]
Sternberg, C. N.
(2009). Expanding the boundaries of clinical practice: building on experience with targeted therapies. Ann Oncol
20: i1-i6
[Abstract][Full Text]
Ravaud, A.
(2009). How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents. Ann Oncol
20: i7-i12
[Abstract][Full Text]
Bellmunt, J.
(2009). Future developments in renal cell carcinoma. Ann Oncol
20: i13-i17
[Abstract][Full Text]
Schoffski, P., Bukowski, R., Flodgren, P., Ravaud, A.
(2009). Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports. Ann Oncol
20: i25-i30
[Abstract][Full Text]
Escudier, B., Kataja, V., On behalf of the ESMO Guidelines Working Group,
(2009). Renal cell carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol
20: iv81-iv82
[Full Text]
Barros Costa, R. L.
(2009). Review Article: Targeted Therapy: Comprehensive Review. AM J HOSP PALLIAT CARE
26: 137-146
[Abstract]
Houk, B. E., Bello, C. L., Kang, D., Amantea, M.
(2009). A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients. Clin. Cancer Res.
15: 2497-2506
[Abstract][Full Text]
Feldman, D. R., Baum, M. S., Ginsberg, M. S., Hassoun, H., Flombaum, C. D., Velasco, S., Fischer, P., Ronnen, E., Ishill, N., Patil, S., Motzer, R. J.
(2009). Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma. JCO
27: 1432-1439
[Abstract][Full Text]
Soria, J.-C., Massard, C., Izzedine, H.
(2009). From Theoretical Synergy to Clinical Supra-Additive Toxicity. JCO
27: 1359-1361
[Full Text]
Xin, H., Zhang, C., Herrmann, A., Du, Y., Figlin, R., Yu, H.
(2009). Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells. Cancer Res.
69: 2506-2513
[Abstract][Full Text]
Ozao-Choy, J., Ma, G., Kao, J., Wang, G. X., Meseck, M., Sung, M., Schwartz, M., Divino, C. M., Pan, P.-Y., Chen, S.-H.
(2009). The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies. Cancer Res.
69: 2514-2522
[Abstract][Full Text]
Ko, J. S., Zea, A. H., Rini, B. I., Ireland, J. L., Elson, P., Cohen, P., Golshayan, A., Rayman, P. A., Wood, L., Garcia, J., Dreicer, R., Bukowski, R., Finke, J. H.
(2009). Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients. Clin. Cancer Res.
15: 2148-2157
[Abstract][Full Text]
Cella, D., Cappelleri, J. C., Bushmakin, A., Charbonneau, C., Li, J. Z., Kim, S. T., Chen, I., Michaelson, M. D., Motzer, R. J.
(2009). Quality of Life Predicts Progression-Free Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib Versus Interferon Alfa. J Oncol Pract
5: 66-70
[Abstract][Full Text]
Lee, J.-O., Lee, K.-W., Kim, C.-J., Kim, Y. J., Lee, H. E., Kim, H., Kim, J. H., Bang, S.-M., Kim, J.-S., Lee, J. S.
(2009). Metastatic Adrenocortical Carcinoma Treated with Sunitinib: A Case Report. Jpn J Clin Oncol
39: 183-185
[Abstract][Full Text]
Klatte, T., Seligson, D. B., LaRochelle, J., Shuch, B., Said, J. W., Riggs, S. B., Zomorodian, N., Kabbinavar, F. F., Pantuck, A. J., Belldegrun, A. S.
(2009). Molecular Signatures of Localized Clear Cell Renal Cell Carcinoma to Predict Disease-Free Survival after Nephrectomy. Cancer Epidemiol. Biomarkers Prev.
18: 894-900
[Abstract][Full Text]
Ma, W. W., Adjei, A. A.
(2009). Novel Agents on the Horizon for Cancer Therapy. CA Cancer J Clin
59: 111-137
[Abstract][Full Text]
Sun, M. R. M., Ngo, L., Genega, E. M., Atkins, M. B., Finn, M. E., Rofsky, N. M., Pedrosa, I.
(2009). Renal Cell Carcinoma: Dynamic Contrast-enhanced MR Imaging for Differentiation of Tumor Subtypes--Correlation with Pathologic Findings. Radiology
250: 793-802
[Abstract][Full Text]
Sharma, A., Sharma, A. K., Madhunapantula, S. V., Desai, D., Huh, S. J., Mosca, P., Amin, S., Robertson, G. P.
(2009). Targeting Akt3 Signaling in Malignant Melanoma Using Isoselenocyanates. Clin. Cancer Res.
15: 1674-1685
[Abstract][Full Text]
Tuthill, M., Barod, R., Pyle, L., Cook, T., Chew, S., Gore, M., Maxwell, P., Eisen, T.
(2009). A report of succinate dehydrogenase B deficiency associated with metastatic papillary renal cell carcinoma: successful treatment with the multi-targeted tyrosine kinase inhibitor sunitinib. BMJ Case Reports
2009: bcr0820080732-bcr0820080732
[Abstract][Full Text]
Bach, P. B.
(2009). Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs. NEJM
360: 626-633
[Full Text]
Winn, S. K., Ellis, S., Savage, P., Sampson, S., Marsh, J. E.
(2009). Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?. Nephrol Dial Transplant
24: 673-675
[Abstract][Full Text]
Reckova, M., Kakalejcik, M., Beniak, J.
(2009). Treatment of hemodialyzed patient with sunitinib. Ann Oncol
20: 392-393
[Full Text]
Cha, T.-L., Chuang, M.-J., Wu, S.-T., Sun, G.-H., Chang, S.-Y., Yu, D.-S., Huang, S.-M., Huan, S. K.-H., Cheng, T.-C., Chen, T.-T., Fan, P.-L., Hsiao, P.-W.
(2009). Dual Degradation of Aurora A and B Kinases by the Histone Deacetylase Inhibitor LBH589 Induces G2-M Arrest and Apoptosis of Renal Cancer Cells. Clin. Cancer Res.
15: 840-850
[Abstract][Full Text]
Stacchiotti, S., Tamborini, E., Marrari, A., Brich, S., Rota, S. A., Orsenigo, M., Crippa, F., Morosi, C., Gronchi, A., Pierotti, M. A., Casali, P. G., Pilotti, S.
(2009). Response to Sunitinib Malate in Advanced Alveolar Soft Part Sarcoma. Clin. Cancer Res.
15: 1096-1104
[Abstract][Full Text]
Hahn, N. M., Reckova, M., Cheng, L., Baldridge, L. A., Cummings, O. W., Sweeney, C. J.
(2009). Patient With Malignant Paraganglioma Responding to the Multikinase Inhibitor Sunitinib Malate. JCO
27: 460-463
[Full Text]
Ma, J., Waxman, D. J.
(2009). Dominant Effect of Antiangiogenesis in Combination Therapy Involving Cyclophosphamide and Axitinib. Clin. Cancer Res.
15: 578-588
[Abstract][Full Text]
Golshayan, A. R., George, S., Heng, D. Y., Elson, P., Wood, L. S., Mekhail, T. M., Garcia, J. A., Aydin, H., Zhou, M., Bukowski, R. M., Rini, B. I.
(2009). Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Therapy. JCO
27: 235-241
[Abstract][Full Text]
Bajetta, E., Guadalupi, V., Procopio, G.
(2009). Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors. JCO
27: 319-320
[Full Text]
Joshua, A. M., Ezzat, S., Asa, S. L., Evans, A., Broom, R., Freeman, M., Knox, J. J.
(2009). Rationale and Evidence for Sunitinib in the Treatment of Malignant Paraganglioma/Pheochromocytoma. J. Clin. Endocrinol. Metab.
94: 5-9
[Abstract][Full Text]
Izzedine, H., Etienne-Grimaldi, M. C., Renee, N., Vignot, S., Milano, G.
(2009). Pharmacokinetics of sunitinib in hemodialysis. Ann Oncol
20: 190-192
[Full Text]
Brugarolas, J.
(2009). Molecular Pathways and Targeted Therapies for Renal Cell Carcinoma. Am Soc Clin Oncol Ed Book
2009: 710-715
[Abstract][Full Text]
Biswas, S., Kelly, J., Eisen, T.
(2009). Cytoreductive Nephrectomy in Metastatic Clear-Cell Renal Cell Carcinoma: Perspectives in the Tyrosine Kinase Inhibitor Era. The Oncologist
14: 52-59
[Abstract][Full Text]
Peppercorn, J., Burstein, H., Miller, F. G., Winer, E., Joffe, S.
(2008). Self-Reported Practices and Attitudes of US Oncologists Regarding Off-Protocol Therapy. JCO
26: 5994-6000
[Abstract][Full Text]
Trippoli, S., Messori, A.
(2008). Cost Effectiveness of Sunitinib. JCO
26: 5829-5829
[Full Text]
Remak, E.
(2008). In Reply. JCO
26: 5829-5830
[Full Text]
Ma, J., Waxman, D. J.
(2008). Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Molecular Cancer Therapeutics
7: 3670-3684
[Abstract][Full Text]
Xue, Y., Religa, P., Cao, R., Hansen, A. J., Lucchini, F., Jones, B., Wu, Y., Zhu, Z., Pytowski, B., Liang, Y., Zhong, W., Vezzoni, P., Rozell, B., Cao, Y.
(2008). Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome. Proc. Natl. Acad. Sci. USA
105: 18513-18518
[Abstract][Full Text]
Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Ou, S.-S., Archer, L., Atkins, J. N., Picus, J., Czaykowski, P., Dutcher, J., Small, E. J.
(2008). Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206. JCO
26: 5422-5428
[Abstract][Full Text]
Hu-Lowe, D. D., Zou, H. Y., Grazzini, M. L., Hallin, M. E., Wickman, G. R., Amundson, K., Chen, J. H., Rewolinski, D. A., Yamazaki, S., Wu, E. Y., McTigue, M. A., Murray, B. W., Kania, R. S., O'Connor, P., Shalinsky, D. R., Bender, S. L.
(2008). Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3. Clin. Cancer Res.
14: 7272-7283
[Abstract][Full Text]
Schmidinger, M., Zielinski, C. C., Vogl, U. M., Bojic, A., Bojic, M., Schukro, C., Ruhsam, M., Hejna, M., Schmidinger, H.
(2008). Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma. JCO
26: 5204-5212
[Abstract][Full Text]
Garfield, D. H., Wolter, P., Schoffski, P., Hercbergs, A., Davis, P.
(2008). Documentation of Thyroid Function in Clinical Studies With Sunitinib: Why Does It Matter?. JCO
26: 5131-5132
[Full Text]
Lacouture, M. E., Reilly, L. M., Gerami, P., Guitart, J.
(2008). Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol
19: 1955-1961
[Abstract][Full Text]
Loriot, Y., Boudou-Rouquette, P., Billemont, B., Ropert, S., Goldwasser, F.
(2008). Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib. Ann Oncol
19: 1975-1975
[Full Text]
Ellis, L. M., Hicklin, D. J.
(2008). Pathways Mediating Resistance to Vascular Endothelial Growth Factor-Targeted Therapy. Clin. Cancer Res.
14: 6371-6375
[Abstract][Full Text]
Finke, J. H., Rini, B., Ireland, J., Rayman, P., Richmond, A., Golshayan, A., Wood, L., Elson, P., Garcia, J., Dreicer, R., Bukowski, R.
(2008). Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients. Clin. Cancer Res.
14: 6674-6682
[Abstract][Full Text]
Hahn, O. M., Yang, C., Medved, M., Karczmar, G., Kistner, E., Karrison, T., Manchen, E., Mitchell, M., Ratain, M. J., Stadler, W. M.
(2008). Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacodynamic Biomarker Study of Sorafenib in Metastatic Renal Carcinoma. JCO
26: 4572-4578
[Abstract][Full Text]
Schneider, B. P., Wang, M., Radovich, M., Sledge, G. W., Badve, S., Thor, A., Flockhart, D. A., Hancock, B., Davidson, N., Gralow, J., Dickler, M., Perez, E. A., Cobleigh, M., Shenkier, T., Edgerton, S., Miller, K. D.
(2008). Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100. JCO
26: 4672-4678
[Abstract][Full Text]
Ng, C. S., Wood, C. G., Silverman, P. M., Tannir, N. M., Tamboli, P., Sandler, C. M.
(2008). Renal Cell Carcinoma: Diagnosis, Staging, and Surveillance. Am. J. Roentgenol.
191: 1220-1232
[Abstract][Full Text]
Stein, W. D., Yang, J., Bates, S. E., Fojo, T.
(2008). Bevacizumab Reduces the Growth Rate Constants of Renal Carcinomas: A Novel Algorithm Suggests Early Discontinuation of Bevacizumab Resulted in a Lack of Survival Advantage. The Oncologist
13: 1055-1062
[Abstract][Full Text]
Hutson, T. E., Figlin, R. A., Kuhn, J. G., Motzer, R. J.
(2008). Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies. The Oncologist
13: 1084-1096
[Abstract][Full Text]
van Cruijsen, H., van der Veldt, A. A.M., Vroling, L., Oosterhoff, D., Broxterman, H. J., Scheper, R. J., Giaccone, G., Haanen, J. B.A.G., van den Eertwegh, A. J.M., Boven, E., Hoekman, K., de Gruijl, T. D.
(2008). Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival. Clin. Cancer Res.
14: 5884-5892
[Abstract][Full Text]
Negrier, S., Perol, D., Ravaud, A., Bay, J. O., Oudard, S., Chabaud, S., Fargeot, P., Delva, R., Deplanque, G., Gravis, G., Escudier, B., for the French Immunotherapy Group,
(2008). Randomized Study of Intravenous versus Subcutaneous Interleukin-2, and IFN{alpha} in Patients with Good Prognosis Metastatic Renal Cancer. Clin. Cancer Res.
14: 5907-5912
[Abstract][Full Text]
Willmann, J. K., Lutz, A. M., Paulmurugan, R., Patel, M. R., Chu, P., Rosenberg, J., Gambhir, S. S.
(2008). Dual-targeted Contrast Agent for US Assessment of Tumor Angiogenesis in Vivo. Radiology
248: 936-944
[Abstract][Full Text]
Telli, M. L., Witteles, R. M., Fisher, G. A., Srinivas, S.
(2008). Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol
19: 1613-1618
[Abstract][Full Text]
Jiang, Z., Chu, P. G., Woda, B. A., Liu, Q., Balaji, K.C., Rock, K. L., Wu, C.-L.
(2008). Combination of Quantitative IMP3 and Tumor Stage: A New System to Predict Metastasis for Patients with Localized Renal Cell Carcinomas. Clin. Cancer Res.
14: 5579-5584
[Abstract][Full Text]
Lacouture, M. E., Wu, S., Robert, C., Atkins, M. B., Kong, H. H., Guitart, J., Garbe, C., Hauschild, A., Puzanov, I., Alexandrescu, D. T., Anderson, R. T., Wood, L., Dutcher, J. P.
(2008). Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib. The Oncologist
13: 1001-1011
[Abstract][Full Text]
Billemont, B., Barete, S., Rixe, O., Niculescu, L., Hariharan, S., Charles, L.
(2008). Scrotal Cutaneous Side Effects of Sunitinib. NEJM
359: 975-976
[Full Text]
Remak, E., Charbonneau, C., Negrier, S., Kim, S. T., Motzer, R. J.
(2008). Economic Evaluation of Sunitinib Malate for the First-Line Treatment of Metastatic Renal Cell Carcinoma. JCO
26: 3995-4000
[Abstract][Full Text]
Crispen, P. L., Sheinin, Y., Roth, T. J., Lohse, C. M., Kuntz, S. M., Frigola, X., Thompson, R. H., Boorjian, S. A., Dong, H., Leibovich, B. C., Blute, M. L., Kwon, E. D.
(2008). Tumor Cell and Tumor Vasculature Expression of B7-H3 Predict Survival in Clear Cell Renal Cell Carcinoma. Clin. Cancer Res.
14: 5150-5157
[Abstract][Full Text]
Rini, B. I., Michaelson, M. D., Rosenberg, J. E., Bukowski, R. M., Sosman, J. A., Stadler, W. M., Hutson, T. E., Margolin, K., Harmon, C. S., DePrimo, S. E., Kim, S. T., Chen, I., George, D. J.
(2008). Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma. JCO
26: 3743-3748
[Abstract][Full Text]
Cella, D., Li, J. Z., Cappelleri, J. C., Bushmakin, A., Charbonneau, C., Kim, S. T., Chen, I., Motzer, R. J.
(2008). Quality of Life in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib or Interferon Alfa: Results From a Phase III Randomized Trial. JCO
26: 3763-3769
[Abstract][Full Text]
Dodd, L. E., Korn, E. L., Freidlin, B., Jaffe, C. C., Rubinstein, L. V., Dancey, J., Mooney, M. M.
(2008). Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?. JCO
26: 3791-3796
[Abstract][Full Text]
Carden, C. P., Larkin, J. M.G., Rosenthal, M. A.
(2008). What is the risk of intracranial bleeding during anti-VEGF therapy?. Neuro Oncol
10: 624-630
[Abstract][Full Text]
Guenova, E., Weber, H. O., Voykov, B., Metzler, G., Mitev, V., Berneburg, M., Hoetzenecker, W., Rocken, M.
(2008). Palmar-Plantar Erythrodysesthesia Secondary to Sunitinib Treatment Resulting in Necrotic Foot Syndrome Aggravated by Background Diabetic Vascular Disease. Arch Dermatol
144: 1081-1082
[Full Text]
Bellmunt, J., Szczylik, C., Feingold, J., Strahs, A., Berkenblit, A.
(2008). Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol
19: 1387-1392
[Abstract][Full Text]
Nickerson, M. L., Jaeger, E., Shi, Y., Durocher, J. A., Mahurkar, S., Zaridze, D., Matveev, V., Janout, V., Kollarova, H., Bencko, V., Navratilova, M., Szeszenia-Dabrowska, N., Mates, D., Mukeria, A., Holcatova, I., Schmidt, L. S., Toro, J. R., Karami, S., Hung, R., Gerard, G. F., Linehan, W. M., Merino, M., Zbar, B., Boffetta, P., Brennan, P., Rothman, N., Chow, W.-H., Waldman, F. M., Moore, L. E.
(2008). Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors. Clin. Cancer Res.
14: 4726-4734
[Abstract][Full Text]
Kulke, M. H., Lenz, H.-J., Meropol, N. J., Posey, J., Ryan, D. P., Picus, J., Bergsland, E., Stuart, K., Tye, L., Huang, X., Li, J. Z., Baum, C. M., Fuchs, C. S.
(2008). Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors. JCO
26: 3403-3410
[Abstract][Full Text]
Brugarolas, J., Lotan, Y., Watumull, L., Kabbani, W.
(2008). Sirolimus in Metatastic Renal Cell Carcinoma. JCO
26: 3457-3460
[Full Text]
Strumberg, D.
(2008). Efficacy of Sunitinib and Sorafenib in Non-Clear Cell Renal Cell Carcinoma: Results From Expanded Access Studies. JCO
26: 3469-3471
[Full Text]
Choueiri, T. K., Bukowski, R. M., Escudier, B.
(2008). In Reply. JCO
26: 3471-3471
[Full Text]
Trotta, F., Apolone, G., Garattini, S., Tafuri, G.
(2008). Stopping a trial early in oncology: for patients or for industry?. Ann Oncol
19: 1347-1353
[Abstract][Full Text]
Chen, M. H., Kerkela, R., Force, T.
(2008). Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics. Circulation
118: 84-95
[Full Text]
Hipp, M. M., Hilf, N., Walter, S., Werth, D., Brauer, K. M., Radsak, M. P., Weinschenk, T., Singh-Jasuja, H., Brossart, P.
(2008). Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood
111: 5610-5620
[Abstract][Full Text]
Hoskin, P.
(2008). Opioids in context: relieving the pain of cancer. The role of comprehensive cancer management. Palliat Med
22: 303-309
[Abstract]
Steeghs, N., Gelderblom, H., Roodt, J. o. t, Christensen, O., Rajagopalan, P., Hovens, M., Putter, H., Rabelink, T. J., de Koning, E.
(2008). Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis Inhibitor. Clin. Cancer Res.
14: 3470-3476
[Abstract][Full Text]
Previous
